Medtech Firms Unite To Fight Bloodstream Infections  

Two Israeli medtech companies have announced a new partnership on developing a bio-electronic treatment that will effectively prevent bloodstream infections in patients admitted to the ICU. 

Inspira Technologies’ innovation involves inserting a cannula into the jugular, which pulls blood with low oxygen levels into an “artificial lung.” The device pumps oxygen into the blood and removes CO2 before sending it back into the body, reaching 95 percent oxygen saturation in about a minute.

The Ra’anana-based company has teamed up with Ennocure, which produces AI-driven, antibacterial wound dressings, to develop the solution. 

The INSPIRA ART device is designed for use while the patient is still awake and can breathe spontaneously and avoids the need for a ventilator that requires an induced coma. 

Once developed, the treatment aims to prevent bacterial infections triggered by intravenous interventions that can cause a bloodstream infection (sepsis). 

“By Integrating our technology to oxygenate blood directly with Ennocure’s infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments,”  said Inspira CEO Dagi Ben-Noon. 

“This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology,” he said.